VCAM-1 as a common biomarker in inflammatory bowel disease and colorectal cancer: unveiling the dual anti-inflammatory and anti-cancer capacities of anti-VCAM-1 therapies
Cancer and Metastasis Reviews · 17.03.2025 · 44 (2)
DOI: 10.1007/s10555-025-10258-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, online erschienen am 17.03.2025. Verfasst von Jessica R Pickett und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Environment and Science, Griffith University, Nathan Campus, Brisbane, 4111, QLD, Australia. Hauptthemen laut MEDLINE: Vascular Cell Adhesion Molecule-1, Inflammatory Bowel Diseases, Colorectal Neoplasms, Anti-Inflammatory Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Griffith University.
Abstract (Originalsprache)
Vascular cell adhesion molecule (VCAM)-1 has garnered significant research attention due to its potential as a disease biomarker and drug target across several inflammatory pathologies—including atherosclerosis, asthma, rheumatoid arthritis, and inflammatory bowel disease (IBD). The VCAM-1 protein has also been noted for its functional involvement in cancer metastasis and drug resistance to conventional chemotherapeutics. Although the anti-inflammatory and anti-cancer facets of VCAM-1 antagonisation have been examined separately, there is yet to be a review that explicitly addresses the functional interrelationship between these mechanisms. Furthermore, the pleiotropic mechanisms of anti-VCAM-1 therapies may present a useful paradigm for designing drug candidates with synergistic anti-inflammatory and anti-tumorigenic effects. The pathological overlap between inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CRC) serves as the quintessential disease model to observe this therapeutic duality. This review thereby details the adhesive mechanisms of VCAM-1 in colorectal disease—specifically, driving immune cell infiltration during IBD and tumour cell metastasis in CRC—and posits the potential of this receptor as a common drug target for both diseases. To explore this hypothesis, the current progress of novel VCAM-1-directed drug candidates in experimental models of IBD and CRC is also discussed. Graphical Abstract TOC Figure: Graphical abstract illustrating the multi-functional role of vascular cell adhesion molecule (VCAM)-1 in colorectal diseases. VCAM-1 facilitates adhesive cell-to-cell attachments via a receptor-ligand binding mechanism with its complementary integrin ligands, α 4 β 1 and α 4 β 7 . These VCAM-1-mediated interactions are involved in both inflammatory cell recruitment during inflammatory bowel disease (IBD) and cancer cell metastasis in colorectal cancer (CRC), highlighting the therapeutic potential of VCAM-1 as a drug target for both pathologies
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Environment and Science, Griffith University, Nathan Campus, Brisbane, 4111, QLD, Australia.
- School of Environment and Science, Griffith University, Nathan Campus, Brisbane, 4111, QLD, Australia. h.ta@griffith.edu.au.
Förderung
- Griffith University
Zitieren
APA
Pickett, J. R., Wu, Y., & Ta, H. T. (2025). VCAM-1 as a common biomarker in inflammatory bowel disease and colorectal cancer: unveiling the dual anti-inflammatory and anti-cancer capacities of anti-VCAM-1 therapies. Cancer and Metastasis Reviews, 44(2). https://doi.org/10.1007/s10555-025-10258-2
Vancouver
Pickett JR, Wu Y, Ta HT. VCAM-1 as a common biomarker in inflammatory bowel disease and colorectal cancer: unveiling the dual anti-inflammatory and anti-cancer capacities of anti-VCAM-1 therapies. Cancer and Metastasis Reviews. 2025;44(2). doi:10.1007/s10555-025-10258-2
BibTeX
@article{Pickett2025,
author = {Pickett, Jessica R and Wu, Yuao and Ta, Hang Thu},
title = {VCAM-1 as a common biomarker in inflammatory bowel disease and colorectal cancer: unveiling the dual anti-inflammatory and anti-cancer capacities of anti-VCAM-1 therapies},
journal = {Cancer and Metastasis Reviews},
year = {2025},
volume = {44},
number = {2},
doi = {10.1007/s10555-025-10258-2}
}
EUVIMED